Clinical Trials Directory

Trials / Completed

CompletedNCT00149383

Safety and Efficacy Study of Adjunctive Rosiglitazone in the Treatment of Uncomplicated Falciparum Malaria

A Randomized, Double-blind, Placebo-controlled Trial of Rosiglitazone as Adjunctive Therapy for P.Falciparum Infection

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
140 (actual)
Sponsor
Mahidol University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to examine the safety, tolerability, and efficacy of adjunctive rosiglitazone in the treatment of uncomplicated P.falciparum malaria.

Detailed description

Study Rationale: Evidence suggests that if PPAR-RXR agonists (such as rosiglitazone) are used as adjunctive therapy in P. falciparum malaria infections they may increase phagocytic clearance of P. falciparum malaria, modulate deleterious inflammatory responses and decrease sequestration of malaria parasites in vital organs. They may therefore represent a novel immunomodulatory treatment approach for P. falciparum malaria. Study Objectives: 1) To examine the in vivo effect of rosiglitazone on the rapidity of clearance of P. falciparum parasitemia and fever in patients with non-severe P. falciparum infections 2) To assess the safety and tolerability of adjunctive rosiglitazone treatment in non-severe cases of P. falciparum infection. Primary Outcomes: Time to clearance of P. falciparum parasitemia Study Design: Randomized double blind placebo-controlled trial. Intervention: Standard antimalarial treatment (atovaquone/proguanil) to all patients combined with adjuvant rosiglitazone treatment (8mg per day) or placebo. Setting: Hospital for Tropical Diseases at Mahidol University, Thailand. Participants: 140 patients with non-severe P. falciparum infection. Follow-up: 28 days

Conditions

Interventions

TypeNameDescription
DRUGRosiglitazone
DRUGPlacebo

Timeline

Start date
2004-12-01
Primary completion
2005-11-01
Completion
2006-01-01
First posted
2005-09-08
Last updated
2015-04-13

Locations

1 site across 1 country: Thailand

Source: ClinicalTrials.gov record NCT00149383. Inclusion in this directory is not an endorsement.